Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 12/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3172779 | 0.99 | OPRK1 (0.51) | OPRK1OPRD1OPRM1LMNAPDE4D | |
| SCHEMBL3183217 | 0.95 | OPRK1 (0.53) | OPRK1OPRD1OPRM1LMNAPDE4D | |
| Hydrochloric Acid SCHEMBL3175088 | 0.94 | OPRK1 (0.53) | OPRK1OPRD1OPRM1LMNAPDE4D | |
| SCHEMBL3173271 | 0.93 | OPRK1 (0.48) | OPRK1OPRD1OPRM1LMNAPDE4D | |
| Hydrochloric Acid SCHEMBL3172713 | 0.93 | OPRK1 (0.47) | OPRK1OPRD1OPRM1LMNAPDE4D | |
| SCHEMBL3167659 | 0.93 | OPRK1 (0.54) | OPRK1OPRD1OPRM1 | |
| Hydrochloric Acid SCHEMBL3172200 | 0.92 | OPRK1 (0.53) | OPRK1OPRD1OPRM1 | |
| SCHEMBL3172796 | 0.92 | OPRK1 (0.57) | OPRK1OPRD1OPRM1LMNAPDE4D | |
| SCHEMBL3175038 | 0.91 | OPRK1 (0.55) | OPRK1OPRD1OPRM1 | |
| SCHEMBL3174891 | 0.91 | OPRK1 (0.54) | OPRK1OPRD1OPRM1LMNAPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554282-B1 | MORPHINAN DERIVATIVES SUBSTITUTED IN POSITION 14 AND QUATERNARY AMMONIUM SALTS THEREOF, METHOD FOR PRODUCTION AND USE THEREOF | ALCASYNN PHARMACEUTICALS GMBH (AT) | 2008-05-28 | — | — | EP | claimed |
| US-20050182258-A1 | Morphinan derivatives the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof | ALCASYNN PHARMACEUTICALS GMBH (AT) | 2005-08-18 | — | — | US | claimed |
| US-7655671-B2 | Morphinan derivatives, the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof | ALCASYNN PHARMACEUTICALS GMBH (AT) | 2010-02-02 | — | — | US | disclosed |
| EP-1554282-B1 | MORPHINAN DERIVATIVES SUBSTITUTED IN POSITION 14 AND QUATERNARY AMMONIUM SALTS THEREOF, METHOD FOR PRODUCTION AND USE THEREOF | ALCASYNN PHARMACEUTICALS GMBH (AT) | 2008-05-28 | — | — | EP | disclosed |
| US-20080064712-A1 | Morphinan derivatives, the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof | ALCASYNN PHARMACEUTICALS GMBH | 2008-03-13 | — | — | US | disclosed |
| US-20050182258-A1 | Morphinan derivatives the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof | ALCASYNN PHARMACEUTICALS GMBH (AT) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182258-A1 | Morphinan derivatives the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof | OPRM1, OPRD1, OPRK1 | OPRK1 3/4885OPRD1 2/4885OPRM1 1/4885 |
| US-20080064712-A1 | Morphinan derivatives, the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof | OPRM1, OPRD1, OPRK1 | OPRK1 3/4885OPRD1 2/4885OPRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.